[Alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab and teriflunomide for the treatment of adult patients with highly active relapsing remitting multiple sclerosis]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005266
Original Title: Alemtuzumab, Cladribin, Dimethylfumarat, Fingolimod, Natalizumab, Ocrelizumab, Ofatumumab, Ozanimod, Ponesimod und Teriflunomid zur Behandlung Erwachsener mit hochaktiver schubförmig remittierender multipler Sklerose
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Multiple Sclerosis, Relapsing-Remitting
  • Alemtuzumab
  • Cladribine
  • Dimethyl Fumarate
  • Fingolimod Hydrochloride
  • Natalizumab
  • Antibodies, Monoclonal, Humanized
  • Sphingosine 1 Phosphate Receptor Modulators
  • Anti-Inflammatory Agents, Non-Steroidal
  • Immunosuppressive Agents
  • Adult
  • Alemtuzumab
  • Cladribine
  • Dimethyl Fumarate
  • Fingolimod Hydrochloride
  • Natalizumab
  • Ocrelizumab
  • Ofatumumab
  • Ozanimod
  • Ponesimod
  • Teriflunomide
  • Multiple Sclerosis – Relapsing-Remitting
  • Benefit Assessment
  • Systematic Review
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: <p>Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.